Navigation Links
A Statement from GlaxoSmithKline Consumer Healthcare on FDA Regulation of Smokeless Tobacco Products

PARSIPPANY, N.J., Sept. 27 /PRNewswire/ -- GlaxoSmithKline (GSK) Consumer Healthcare, a leader in helping smokers quit and the marketer of nicotine replacement therapy (NRT) products, including Nicorette® and NicoDerm® CQ®, supports the findings of the American Heart Association (AHA) policy statement regarding smokeless tobacco products.(1) GSK Consumer Healthcare agrees that these products should not be used as an alternative to cigarettes or for smoking cessation due to the potential negative health consequences and their impact on smoking behavior. 

The AHA statement is important because the U.S. Food and Drug Administration (FDA) has just finished accepting comments from the public on how FDA should regulate certain smokeless tobacco products.  GSK Consumer Healthcare submitted a comment to the FDA on the potential public health impact of oral dissolvable tobacco products.  In our submission, GSK Consumer Healthcare called for oral dissolvable tobacco products to be withdrawn from the market until their sponsors can demonstrate to FDA that their marketing is appropriate for the protection of public health.

The AHA policy statement, notes that smokeless tobacco products are not safe alternatives to smoking and are associated with heart attack, stroke and certain cancers.(1)  Also, due to the marketing of these products, smokeless tobacco products may also initiate further tobacco use and perpetuate smoking.(1) 

Tobacco use, including smokeless tobacco, is the largest cause of preventable death and disease in the world.(2)  More than 400,000 Americans die every year from tobacco-related disease.(2)  The only proven way to reduce these health consequences is to stop using tobacco completely.  Smokeless tobacco products are currently being marketed without clear evidence of their safety.

NRT products alternatively, have helped millions of people around the world quit smoking and, as a result, have significantly reduced their exposure to the risks of cancer and other smoking-related diseases.(3)  GlaxoSmithKline Consumer Healthcare believes that before considering a potential role for oral dissolvable tobacco products in reducing the adverse health effects of smoking, there are significant opportunities to enhance the impact of existing smoking cessation aids, including expanding access to and use of NRT products. While the FDA is the final authority on the labeling of NRT products sold in the U.S., GSK Consumer Healthcare is committed to continuing to work with medical and clinical experts, and the FDA, to ensure that consumers have the best possible chance to quit smoking.

Quitting smoking is the single most important step smokers can take to improve their health – and it's also one of the most difficult.  By developing innovative new products and support systems to improve the quit experience, and helping to make the products as accessible as possible, GSK Consumer Healthcare works to inspire and enable every smoker to quit for good.

  1. Piano, et al. Impact of Smokeless Tobacco Products on Cardiovascular Disease: Implications for Policy, Prevention, and Treatment. A Policy Statement From the American Heart Association. Circulation published online Sep 13, 2010. Available at
  2. Centers for Disease Control and Prevention. Targeting Tobacco Use: The Nation's Leading Cause of Preventable Death. Available at
  3. GSK data on file.

SOURCE GlaxoSmithKline Consumer Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott Statement on the FDA Advisory Committee Recommendation on Sibutramine
2. Statement from CHPA on Todays FDA Advisory Committee Meeting on Dextromethorphan
3. Media Statement: Robert Moussa, President and CEO, Dilon Diagnostics
4. Statement from Eli Lilly and Company Regarding Approval Recommendation from FDA Advisory Committee for Expanding the Pain Indications for Cymbalta® to a Broader Pain Population
5. Horizon Pharma, Inc. Files Registration Statement for Proposed Initial Public Offering
6. NCPA Statement on CVS Caremark-Aetna Agreement
7. GlaxoSmithKline Statement in Response to FDA Advisory Committees Vote on Safety of Avandia® (rosiglitazone)
8. Dendreon Statement on CMS National Coverage Analysis
9. NORD Calls for Statement of Policy on Orphan Drug Development
10. Teva Admits to Making False Statements in US Gianvi™ Label and Agrees to Corrective Measures
11. Alexza Pharmaceuticals Files Shelf Registration Statement
Post Your Comments:
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Italian therapeutic drug monitoring market, including emerging ...
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: AMGN ... Application (BLA) with the United States ... 501, a biosimilar candidate to Humira ® (adalimumab). ... application submitted to the FDA and represents Amgen,s first ... Sean E. Harper , M.D., executive vice president of ...
(Date:11/25/2015)... Nov. 25, 2015  ARKRAY USA ... to provide evidence demonstrating the accuracy of its blood ... on Insulin Resistance, Diabetes and Cardiovascular Disease in ... the Company,s GLUCOCARD ® 01 meter and the ... requirements. The ability to accurately measure glucose levels in ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... , ... Safe storage for contraceptive devices may not always be easy to ... and the other from Bradley Beach, New Jersey, there is an easy solution to ... to replace NuvaRings more often than necessary. As such, it affords peace of mind ...
(Date:11/27/2015)... ... November 28, 2015 , ... There is only one major question facing ... last year? , This question has not been an easy question to answer. Especially ... age and the younger workforce don’t share the same discipline around working long hours. ...
(Date:11/27/2015)... ... 27, 2015 , ... The rapid speed at which Americans ... more care is needed, especially with Alzheimer’s, dementia and other cognitive conditions becoming ... The forgotten part of this equation: 80 percent of medical care occurs in ...
(Date:11/27/2015)... ... 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion that ... of their purchase of lice treatment product. In addition, customers will receive a complimentary ... spokesperson. “Finding lice is a sure way to ruin the holidays, so we encourage ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... of progress through sharing, the 2016 Building Better Radiology Marketing Programs ... will begin on Sunday, March 6, 2016, at Caesars Palace in Las Vegas ...
Breaking Medicine News(10 mins):